LTRN

Lantern Pharma

--

--(--)

Market Open: --

--

--(--)

Post-Market: --

Signals Analysis

Buy signal 2

Sell signal 0

consensus rating "Strong Buy"

EPS Beats Expectation

Key Stats

--DAY`S RANGE--

--52 WK RANGE--

Open

--

Prev.Close

--

%Range

--

Turnover

--

Avg Vol(4W)

--

Market Cap

--

Div.Yield

--

P/E(TTM)

--

EPS(TTM)

--

Beta

--

Free Float

--

Shares Outstanding

--

%Turnover

--

P/E(DYN)

--

P/B

--

BVPS

--

High

--

Low

--

52 Week High

--

52 Week Low

--

About LTRN

Lantern Pharma Inc.

A clinical stage biopharmaceutical company that develops oncology-based therapeutics for the treatment of cancer

Industry

Biological Technology

Established Date

11/07/2013

Listing Date

06/11/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

24

Fiscal Year Ends

12-31

Website

www.lanternpharma.com

Security Type

Common stock

Office address

1920 McKinney Avenue, 7th Floor, Dallas, Texas 75201

Business

--

Introduction

Lantern Pharma Inc., was founded on November 7, 2013. The company is a clinical-stage biotechnology company that leverages artificial intelligence (" A.I. "), machine learning and genomic data to simplify drug development processes and enable patients to be treated to benefit from its targeted tumor therapies.

Company Financials

EPS

LTRN has released its 2024 Q4 earnings. EPS was reported at -0.54, versus the expected -0.51, missing expectations. The chart below visualizes how LTRN has performed over recent quarters, highlighting trends in earnings surprises.